Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Fig. 3

Plasma L858R abundance in the neoadjuvant TKI setting. Abbreviations: PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. One week after the R0 resection, the abundance of plasma L858R decreased significantly, but it rebounded soon after progression. However, the PR in the first- and second-line TKI therapy did not decrease the level of plasma L858R for one case

Back to article page